Erasca (ERAS) has surged 460% over the past year, driven by strong technical momentum. ERAS hit a new 3-year high of $10.92 on Monday. Despite bullish technicals, ERAS has no revenue, is burning cash, and its future hinges on FDA drug approvals. Analyst sentiment is highly speculative, with price targets ranging from$2 to $16. Today’s Featured Stock Valued at$3.25 billion, Erasca (ERAS) is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercia ...